Inflammatory bowel disease (IBD) is a condition that most people are probably familiar with. It affects the intestine and may steadily progress or repeatedly flare up and calm down. And two main types of IBD come to light: (1) ulcerative colitis (UC) and (2) Crohn’s disease (CD).
Ulcerative colitis affects the rectum and colon alone while Crohn’s disease can affect any part of the intestinal tract from the mouth to the anus, which can lead to complications like abscesses, strictures, and fistulas. But both of these conditions typically affect organs including the joints, skin, and eyes.
According to Harvard Health, IBD has been traditionally thought of as a disease that largely affects people who are white but there has been an observed increase in IBD among other racial and ethnic groups. Research may have only been studying predominantly white participants instead of including underserved populations.
A study by Belton, et al (2022) has shown that there is a barrier that exists between more privileged and underserved populations when it comes to studying, treating, and maintaining IBD. Primarily, it may be because there is a lack of culturally appropriate education and information in patients’ primary languages, specifically, patients cited that they had not received information regarding the connection between IBD and required vaccinations.
Fortunately, ulcerative colitis and Crohn’s disease are both treatable conditions. Treating them ultimately aims to achieve stable remission to stop or ease symptoms and ensure a high quality of life. But the kind of health disparity between privileged and underserved communities can be detrimental to the health and well-being of the latter. Because of this, it’s understandable that underserved communities may find it difficult to address IBD issues.
This is a gap discovered by Evinature and is now being addressed through their clinically tested natural remedies & treatment plans.
Fusing Modern and Traditional Medicine
Evinature works to bridge the gap between traditional and modern medicine. Because society favors evidence-based medicine and practices, it trusts the quality of treatment provided by the medical community. This is difficult for communities that do not have access to advanced and often more expensive treatment.
Upon studying and discovering the potential of curcumin–which is a compound found in turmeric–co-founders Prof. Shomron Ben-Horin, Nir Salomon, and Apan Amos Damri set out to discover how it can address IBD issues, including UC and CD. With their continuous research, they’ve discovered that curcumin relieves intestinal inflammation as well as a treatment for ulcerative colitis and Crohn’s disease.
The compound has drawn clinical interest due to its beneficial antioxidant, anti-inflammatory, anticancer, and neuroprotective properties. With patients in underserved communities not having access to pharmaceutical therapy, Evinature now focuses on prioritizing patient global accessibility to accurate medical assessments and affordable treatment. And they make it possible by creating and providing affordable solutions to patients with IBD, including their proprietary CurQD Protocol.
A Nutraceutical Formula
Evinature’s CurQD Protocol is a set of natural, clinically-proven regimens that are highly individualized to address each stage of a patient’s condition. Through their free online assessment, Evinature provides the most effective protocol for patients’ specific needs. After this, patients’ progress is tracked and they are guided through each stage of the protocol with regular free follow-ups and full clinic support.
But most of all, because of the evolving body of research Evinature builds upon, they give back to the community–especially to underserved communities who can only rely on traditional medicine to address IBD concerns. Going through the Evinature Standard, every study the company conducts goes through rigorous peer review, double-blind administration, and placebo-controlled methods which are then integrated into the world’s leading medical centers and published in high-impact medical journals.
This method helps underserved communities gain access to treatments that pass medical standards while still maintaining affordability.
Leveling the Playing Field for Underserved Communities
In a world where there is a plethora of racial, ethnic, and sociodemographic disparities in therapeutics and outcomes for IBD, including disease severity, morbidity, and mortality, it’s rare to find organizations that are dedicated to elevating the support that underserved communities receive.
But based on research by Odufalu, Aboubakr, and Anyane-Yeboa (2022), it’s possible to achieve equitable access to IBD treatment by tackling structural racism as a driver of health disparities and making actionable changes against multi-level barriers to care. With this possibility, Evinature is taking the lead in tackling this challenge.
